Brief: HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Soligenix

14/01/2025 12:34

Jan 14 (Reuters) - Soligenix Inc  SNGX.O :
    * HYBRYTE™ EXPANDED TREATMENT CONTINUES TO DEMONSTRATE
POSITIVE
OUTCOMES IN EARLY-STAGE CUTANEOUS T-CELL LYMPHOMA

Source text:  ID:nPn6XKpbva 
Further company coverage:  SNGX.O 

 ((Reuters.Briefs@thomsonreuters.com;))